SCHEMBL512291

SCHEMBL512291

COCC(N)C1CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25376958 1.00
SCHEMBL3997892 1.00
Hydrochloric Acid SCHEMBL638383 0.97
Hydrochloric Acid SCHEMBL1633435 0.97
Hydrochloric Acid SCHEMBL1559697 0.97
SCHEMBL28907306 0.90
SCHEMBL28907305 0.90
SCHEMBL6219656 0.88 EPHX1 (0.39)
SCHEMBL89990 0.88 EPHX1 (0.39)
SCHEMBL90261 0.88 EPHX1 (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12497382-B2 GLP-1R modulating compounds GILEAD SCIENCES, INC. (US) 2025-12-16 US disclosed
US-20250136594-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2025-05-01 US disclosed
EP-4469438-A1 COMPOUNDS AND METHODS OF USE Tango Therapeutics, Inc. (US) 2024-12-04 EP disclosed
US-20240270740-A1 INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF VENTUS THERAPEUTICS U.S., INC. 2024-08-15 US disclosed
US-20230391747-A1 GLP-1R MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2023-12-07 US disclosed
WO-2023146987-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed
US-11702404-B2 GLP-1R modulating compounds GILEAD SCIENCES, INC. (US) 2023-07-18 US disclosed
CN-110143955-B Oxadiazole derivative containing heterocyclic side chain, synthetic method and application thereof 中国科学院上海药物研究所 2023-01-20 CN disclosed
EP-4048664-A1 GLP-1R MODULATING COMPOUNDS GILEAD SCIENCES, INC. (US) 2022-08-31 EP disclosed
CN-114630823-A GLP-1R modulating compounds 吉利德科学公司 2022-06-14 CN disclosed
US-20110124662-A1 Substituted Carbamate Derivatives as Modulators of Corticotropin-Releasing Factor Receptor Activity BRISTOL-MYERS SQUIBB COMPANY 2011-05-26 US disclosed
US-7932256-B2 (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile: a pyrazinone modulator of corticotropin-releasing factor receptor activity BRISTOL-MYERS SQUIBB COMPANY (US) 2011-04-26 US disclosed
EP-2307024-A1 SUBSTITUTED CARBAMATE DERIVATIVES AS MODULATORS OF CORTICOTROPIN-RELEASING FACTOR RECEPTOR ACTIVITY Bristol-Myers Squibb Company (US) 2011-04-13 EP disclosed
EP-2303867-A1 PYRAZINONE MODULATOR OF CORTICOTROPIN-RELEASING FACTOR RECEPTOR ACTIVITY Bristol-Myers Squibb Company (US) 2011-04-06 EP disclosed
WO-2011014535-A1 COMPOUNDS FOR THE REDUCTION OF β-AMYLOID PRODUCTION BRISTOL-MYERS SQUIBB COMPANY (US) 2011-02-03 WO disclosed
WO-2010014280-A1 PYRAZINONE MODULATOR OF CORTICOTROPIN-RELEASING FACTOR RECEPTOR ACTIVITY BRISTOL-MYERS SQUIBB COMPANY (US) 2010-02-04 WO disclosed
WO-2010014687-A1 SUBSTITUTED CARBAMATE DERIVATIVES AS MODULATORS OF CORTICOTROPIN-RELEASING FACTOR RECEPTOR ACTIVITY BRISTOL-MYERS SQUIBB COMPANY (US) 2010-02-04 WO disclosed
US-20100029684-A1 Pyrazinone Modulator of Corticotropin-Releasing Factor Receptor Activity BRISTOL-MYERS SQUIBB COMPANY 2010-02-04 US disclosed
WO-2009006492-A2 STEREOSELECTIVE RESOLUTION OF RACEMIC AMINES BRISTOL-MYERS SQUIBB COMPANY (US) 2009-01-08 WO disclosed
WO-2009006492-A2 STEREOSELECTIVE RESOLUTION OF RACEMIC AMINES BRISTOL-MYERS SQUIBB COMPANY (US) 2009-01-08 WO disclosed